MASLD-HCC is now the fastest rising cause of HCC and the fastest growing indication for orthoptic liver transplantation (from 2.1% to 16.2% from 2000 to 2016) . Dynamic Markov modelling for MASLD-HCC across eight countries predicts a 122% rise in its incidence by 2030 [ …

Apr 9, 2024 · Phenotyping MASLD-HCC would contribute to optimizing the identification of MASLD subjects with a greater risk of HCC, refine screening strategies in noncirrhotic populations, design personalized therapeutic approaches for MASLD, and individualize the systemic therapy in MASLD-HCC.

Compared with healthy controls, patients with MASLD had an 8.6-fold increase in HCC risk. Patients with MASLD-associated cirrhosis showed a further marked increase in HCC risk, with an annual incidence of 0.8–2.3% per year. Approximately 20% of all hepatic steatosis-associated HCC cases occurred without predisposing cirrhosis .

Oct 1, 2024 · We found not only a significant increase in MASLD-related HCC but also that MASLD had become the second most-frequent liver disease underlying HCC in the Angers center, now accounting for one-fifth of the cases therein.

We delve into MASH-HCC-associated genetic variations and somatic mutations, disease progression and research models, multiomics analysis, immunological and microenvironmental impacts, and discuss targeted/combined therapies to overcome immune evasion and the biomarkers to recognize treatment responders.

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the latest term for steatotic liver disease associated with metabolic syndrome. MASLD is the most common cause of chronic liver disease and is the leading cause of liver-related morbidity and mortality.

Jan 6, 2024 · Metabolic-dysfunction-associated steatotic liver disease (MASLD, previously known as non-alcoholic fatty liver disease (NAFLD)) represents a rapidly increasing cause of chronic liver disease and hepatocellular carcinoma (HCC), mirroring increasing rates of obesity and metabolic syndrome in the Weste …

The overall risk of HCC in MASLD patients is lower than in other etiologies of liver disease; however, is responsible for up to 35% HCC cases given its high prevalence. A significant proportion of MASLD patients with HCC do not have cirrhosis.

Mar 30, 2024 · Emerging data indicate that specific characteristic changes in the gut microbiome are associated with MASLD and even cirrhosis, which is the primary driver of HCC development [31,41,42]. In MASLD-related HCC and viral hepatitis-related HCC (hepatitis B), specific modification of gut microbiota may represent a potential therapeutic option for ...

Jun 3, 2024 · This review delves into the pathogenesis, diagnosis, and monitoring of MASLD-HCC, alongside treatment options and preventative measures. Presently, the underlying mechanisms of MASLD-HCC are still under investigation, with a notable deficiency in effective screening tools, preventive measures, and curative medications.